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A B S T R A C T
Orally disintegrating tablets (ODTs) are gaining importance and popularity due to their numerous advantages.
Lysozyme, an enzyme with antibacterial properties, is currently only available as a conventional tablet and
syrup. The main aims of this study were to formulate ODTs containing lysozyme using a variety of excipients and
evaluate how formulation technology and excipient selection affected enzyme activity. Three different super-
disintegrants in two concentrations, two different types of fillers, and three types of modern, ready-to-use co-
processed excipients were investigated. The effect of the quality of the materials and the applied compression
force were also studied. The investigated Critical Quality Attributes were disintegration time, dissolution profile
and activity of lysozyme enzyme. A higher enzyme activity was found for ODTs with a higher hardness and
density, containing the stabilizing agent in a smaller particle size. The structure of the superdisintegrant crystals
had a greater impact on the disintegration time and dissolution profile of ODTs than the amount of super-
disintegrants used. The results also revealed that despite the general advantages and effectiveness of ready-to-
use excipients, the use of tailored formulations is more advantageous for sensitive drugs like enzymes.
1. Introduction
Lysozyme is a natural enzyme that can be found in human mucus,
saliva, and tears and also in hen egg white. Lysozyme exhibits a strong
antibacterial activity against Gram-positive bacteria and a weaker ac-
tivity against Gram-negative bacteria [1]. Lysozyme is widely used in
dietary supplements, and it is highly valued to treat headaches, cold
and throat infections, for example, in Malaysia, and lysozyme is also
used as an antimicrobial preservative in foods [2]. Furthermore, a re-
cent study suggests [3] that lysozyme may be effective in the treatment
of certain chronic gastrointestinal inflammations, such as ulcerative
colitis, Crohn's colitis, and Barrett's oesophagitis. Lysozyme can also be
used during COPD treatment as a mucolytic enzyme [4].
Lysozyme is available on the global market only as a conventional
tablet and syrup [2] and, despite the numerous advantages of this do-
sage form, it has not yet been incorporated into orally disintegrating
tablets (ODTs). ODT as a solid dosage form can be administered with or
without water and disintegrates rapidly, usually within a matter of
seconds (30 s or less according to the United States Pharmacopoeia
(USP) disintegration test) when placed upon the tongue [5]. ODTs are
gaining importance and popularity among novel oral drug delivery
systems, as they are convenient to administer, and can offer improved
patient adherence, especially in the case of the elderly and the pediatric
populations, which may have difficulty swallowing conventional tablets
or capsules [6–8]. Furthermore, ODTs may provide improved bioa-
vailability, since the drug starts to absorb in the mouth, which means
reduced first pass effect and greater stability for drugs that are sensitive
for the lower GI conditions (e.g., proteins).
ODTs can be produced by a variety of manufacturing techniques,
including lyophilization, molding, sublimation, and sugar-floss system
[9], but direct compression is still the simplest and most cost-effective
process from the perspective of industrial manufacturing. Direct com-
pression allows for the use of conventional tablet manufacturing
equipment and inexpensive, readily available pharmaceutical ex-
cipients to produce ODTs [10]. Among the various excipients are sev-
eral groups that play a crucial role in ODT formulations: super-
disintegrants, which ensure the rapid dissolution; and multifunctional
filler-binders, which may ensure acceptable mouthfeel in order to en-
sure patient compliance [11,12]. Based on the disintegrating method,
including swelling, wicking, deformation and disintegrating particle/
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particle repulsive forces, four types of superdisintegrants are available
on the market today [13]. Among them, sodium starch glycolate,
crospovidone, and croscarmellose sodium are the most commonly used.
As filler-binders, saccharides such as mannitol, trehalose, xylitol, sor-
bitol and dextrin may be used. These widely used bulking agents pro-
vide a smooth and pleasant mouthfeel, along with a sweet taste. Ad-
ditionally, they dissolve rapidly in the saliva; thus, their use is also
preferred for the characteristic of rapid disintegration [14]. In the
present study, applicability of mannitol and trehalose was tested since
these materials are widely used protectants against thermal stress in
protein processing [15]. High temperatures may occur for milliseconds
during direct compression, which may affect the structure of proteins
and, therefore, their activity [16].
Besides the traditional excipients, more and more excipient manu-
facturers offer special co-processed compounds for different purposes,
such as for direct compression of OTDs. The benefits of these ready-to-
use components include multifunctionality, simplified formulation de-
velopment, and a cost-effective direct compression process. When using
such ingredients, their potential influence on tablet properties, such as
crushing strength, dissolution, and friability should be taken into ac-
count [17–19]. ODTs are the focus of recent pharmaceutical develop-
ments, but despite of their advantages in this field, information on
protein-containing ODTs is limited. Therefore, the main goal of the
present study was the investigation of how the quality of generally used
excipients and processing parameters influence the critical quality at-
tributes, including tablet hardness, disintegration time, dissolution rate
and enzyme activity, of lysozyme-containing ODT formulations.
2. Materials and methods
2.1. Materials
Lysoch™, a lysozyme, was used as the model active ingredient in this
study; it was provided by Handary SA (Brussels, Belgium). The ready-
to-use tableting excipients in this study were received as gifts from
suppliers; they included Prosolv® ODT G2 (a mixture of a filler, binder,
superdisintegrant and glidant, JRS Pharma LP, USA), Prosolv® EASYtab
(a mixture of a filler, glidant, superdisintegrant and lubricant, JRS
Pharma LP, USA), and Ludiflash® (a mixture of a filler, binder, and
disintegrant, BASF Corporation, USA). Two different types of crospo-
vidone, namely Kollidon® CL-SF (BASF, Germany) and Polyplasdone®
XL 10 (GAF Chemicals Corporation, USA), as well as sodium starch
glycolate (Primojel®, DFE Pharma, Germany) were used as super-
disintegrants; all were received as gifts. Concentrations of super-
disintegrants used in this study (i.e., 5% and 10%) were based on the
manufacturers’ general recommendations. Spray-dried mannitol
(Pearlitol® SD 200, Roquette Pharma, France) and trehalose (Cargill,
USA) were employed as fillers and were received as gifts. Prosolv®
SMCC HD 90 was used as a binder and PRUV® as a lubricant; both
ingredients were received as gifts from JRS Pharma LP, USA. The
composition of each type of tablet is shown in Table 1. Micrococcus
lysodeikticus (Sigma Aldrich Co. LLC, USA) was used for the enzyme
activity tests.
2.2. Methods
2.2.1. Preformulation studies
The individual particles of each excipient were examined to study
the surface morphology with an FEI Quanta 3D FEG Dual Beam (FEI,
Hillsboro, OR, USA) scanning electron microscope in Toledo, Ohio,
operated at 5 kV. Samples from each excipient were mounted onto a
double-sided copper conductive tape (NEM Nisshin EM Co. Ltd.) fixed
on aluminum stubs. They were then sputter-coated with a thin layer of
gold in a vacuum for 45 s at 20mA, using a coating unit (Cressington
108 auto sputter coater, UK) to make them electrically conductive.
Scanning electron micrographs of the prepared tablets were taken
and analyzed in Szeged with a Hitachi S-400 (Hitachi Ltd., Tokyo,
Japan) scanning electron microscope. Tablets were fixed on a double-
sided carbon adhesive tape. A SEM sputter coating unit (Polaron E5100,
VG Microtech, UK) was used to charge the surfaces for the SEM mea-
surements. The air pressure was 1.3–13mPa. The SEM was operated at
10 kV. The scanning electron micrographs were used for particle size
evaluation, the particle size was determined by ImageJ software (Image
J 1.51n; National Institute of Health, Bethesda, USA).
The flowing properties of the powder mixtures were examined ac-
cording to USP35 [20].
2.2.2. Preparation of powder mixtures for ODTs
The powders for the 300mg ODTs were mixed using a Turbula
mixer (Clifton, NJ, USA). All ingredients except for the lubricant were
blended for 8min. Then, sodium stearyl fumarate lubricant was added
to the mixture, and it was blended for 2 additional min.
2.2.2.1. Preparation of ODTs. ODTs of 300mg were prepared using a
Korsch EK0 eccentric tablet press (Korsch GmbH, Berlin, Germany) and
standard concave punches and die 0.375 inches (9.525mm) in
diameter. Fifteen different ODTs were made using different powder
mixtures, as shown in Table 1. Series A, B and C were made of
conventional physical powder mixtures, while series D was prepared
using special ODT ready-to-use excipient composites. The compression
force was adjusted to produce tablets with three different theoretical
hardness values: 30 N, 50 N and 70 N. The real hardness values were
deviated around the theoretical within a± 5N range. The reason for
this was to compare the disintegration of tablets with similar
mechanical parameters. In total, 45 different batches of tablets were
made. The tableting process, as well as the final storage of the ODTs,
took place in a conditioned room at 21 ± 0.5 °C and 30 ± 5% RH.
2.2.2.2. Physical evaluation of ODTs. Physical tablet parameters
evaluated included weight uniformity, diameter, thickness, hardness
and friability. The weight of ten tablets was measured in grams.
Thickness, diameter and hardness of ten tablets were measured with
a Sotax Hardness Tester Model HT1 (Sotax GmbH, Allschwil,
Switzerland) in mm and Newtons (N), respectively.
Friability was evaluated according to USP 34, using an Erweka
Friability Apparatus Model TAP 23644 (Erweka GmbH, Heusenstamm,
Germany). Measurements were performed in triplicate. Tablets were
brushed to remove excess powder, both prior to their initial weight
determination and after 100 revolutions (4min at 25 rpm). The per-
centage of weight loss for 6.5 g of total tablet weight was calculated
with Equation 1. According to USP 34, less than 1% loss and no tablet
breakage is acceptable for 100 revolutions in 4min [21].
=Friability initial weight final weight
initial weight
x( ) 100%
Equation 1. Calculation of friability.
2.2.2.3. Performance evaluation of ODTs. For the disintegration studies,
six tablets were tested according to the USP 34 standard method, using
an Erweka model ZT2 apparatus (Erweka GmbH, Heusenstamm,
Germany). The time necessary for each tablet to disintegrate at
37 ± 0.5 °C in DI water to the point where it was small enough to
pass through the mesh at the bottom of the basket was recorded using a
stopwatch. According to the FDA guideline, a time of less than 30 s is
recommended for a product to be considered an ODT [5].
Dissolution studies were performed according to the USP 34 stan-
dard method (Apparatus 2), using a Sotax AT (Sotax, Westborough MA,
USA) dissolution tester. 900mL of DI water with a pH of 6.7–6.9 (at
37 ± 0.5 °C) was used as the dissolution medium. Aliquots of 4.5mL
were taken manually from the dissolution medium at regular time in-
tervals (10, 20, 30, 40, and 50 s, and then1, 1.5, 2, 2.5, 3, 4, 5, 7.5, 10,
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12.5 and 15min) for all samples, without replacing the medium.
Medium loss was taken into account during the calculations. The ab-
sorbance of lysozyme was analyzed at 281 nm, using an Agilent 8453
UV-Vis spectrophotometer (Santa Clara, CA, USA) and Graphpad Prism
(GraphPad Software, Inc., CA, USA).
One of the main aims of this study was to incorporate lysozyme with
mannitol or trehalose into ODTs. The enzyme activity of lysozyme was
evaluated to ensure that the tablet manufacturing process did not affect
negatively the active ingredient's main function. The enzyme activity
was examined directly via measuring the degradation kinetic of
Micrococcus lysodeikticus. The enzymatic rate determination is based on
the following reaction [22]:
Micrococcus lysodeikticus cells intact
Lysozyme
Micrococcus lysodeikticus cells lysed
( )
( )
A Genesys 10S UV-Vis Spectrometer (Thermo Fisher Scientific Inc,
Waltham, MA, USA) was used for the detection. For sample prepara-
tion, one tablet of each mixture was dissolved in 75.0mL, pH=6.25
phosphate buffer, after being filtered through a Chromafil Xtra 0.45-
micron filter (Macherey-Nagel GmbH &Co. KG, Düren, Germany). The
100 μL sample was added to 2.5 mL of 0.2 mg/mL bacterial suspension
(0.0100 g bacteria were suspended in 50mL, pH=6.25 phosphate
buffer for 20 tests); it was then homogenized, and absorbance was
measured at 450 nm every 5 s between 20 s and 5min 20 s. The kinetic
was compared to a 0.4mg/mL lysozyme solution's kinetics.
The results were analyzed by Statistica for Windows v12 software
(Statsoft Inc., Tulsa, OK, USA) using factorial ANOVA method; the level
of significance was p < 0.05.
3. Results and discussion
3.1. Physical evaluation of the ODTs
The morphological characteristics (spherical agglomerates of dried
droplets) of lysozyme (Fig. 1a) suggest that it was crystallized with the
spray drying method. The good sphericity and relatively big particle
size are intended to provide good powder rheological properties. Pro-
solv SMCC (Fig. 1c) had anisometric particles, with an average particle
size of 90 μm. Amongst the stabilizers, the spray-dried particles of
Pearlitol SD 200 (Fig. 1b) were spherical with a 100 μm average particle
size, while trehalose (Fig. 1b) had bigger columnar-isometric, smooth
surfaced crystals with a particle size of 300–500 μm. This suggests that
Pearlitol may be distributed more uniformly in the tablets. The in-
vestigated disintegrants had different structures, which may explain the
differences in their effectiveness. Primojel (Fig. 1g) had considerably
large, spherical and smooth-surfaced particles with an average particle
size of 50 μm. By contrast, Kollidon CL-SF (Fig. 1e) and Polyplasdone
XL-10 (Fig. 1f) were both agglomerates of smaller, platelet-like crystals
with an approximate particle size of 3–5 μm. Nevertheless, there are
considerable differences of their structures. The agglomerates of Kol-
lidon CL-SF were fluffy with a rough surface, while Polyplasdone XL-10
formed more densified, spherical and smooth-surfaced particle ag-
glomerates.
Table 2 presents the results of the powder mixtures' flow test. As it
was expected based on the morphological studies, all the results fell into
the USP's excellent category (i.e., 25–30°). Thus, it was concluded that
the powder mixtures were suitable for direct compression.
The compressed ODTs were analyzed for weight uniformity, dia-
meter, thickness, friability, and hardness (Tables S1–3), and apparent
density of tablets was calculated. All ODTs passed the friability test and
exhibited appropriate mechanical strength. However, the edges of ta-
blets with 30 N hardness were chipped, indicating 30 N as a minimum
level of suitable tablet hardness. There were no visual defects on tablets
with 50 N and 70 N hardness values.
The setting of hardness was appropriate. There was no significant
difference between the theoretical and actual hardness values of sam-
ples; only the hardness of the 70 N mannitol- and trehalose-containing
tablets of series A differed significantly from one another.
The statistical results (see supplementary material) revealed that the
apparent density of tablets showed significant differences according to
all studied factors. There was no significant difference between the
densities of series A and B, both containing crospovidone. However,
series C, containing sodium starch glycolate, exhibited a significantly
higher density (Fig. 2). The increase of the disintegrant content sig-
nificantly decreased the measured densities. Samples with trehalose
exhibited a significantly higher density than samples with mannitol.
Furthermore, it was revealed that there was a significant interaction
between the disintegrants and fillers from the aspect of tablet texture.
ODTs with Polyplasdone exhibited less difference than other composi-
tions, especially at 50 N theoretical hardness (Fig. 2), which also in-
fluenced the disintegration performance of the ODTs.
3.2. Performance evaluation of the ODTs
The results of the disintegration tests are shown in Table 3. It can be
concluded that ODTs containing Polyplasdone® XL-10 as a super-
disintegrant (series B) had the shortest disintegration times. With the
exception of one, all ODTs disintegrated in less than 30 s (the one ex-
ception was still under 50 s). Furthermore, series B tablets exhibited the
least sensitivity to tablet hardness and the applied filler (Fig. 3). The
various ODTs containing Kollidon CL-SF (series A) exhibited similar
Table 1
Composition of ODTs.
Series Ingredients used (%)
Lysozyme Kollidon CL-SF Polyplasdone XL 10 Primojel Pearlitol SD200 Trehalose Prosolv SMCC PRUV Prosolv EASYtab Prosolv ODT G2 Ludiflash
A1 10.0 5.0 – – 54.0 – 30.0 1.0 – – –
A2 10.0 5.0 – – – 54.0 30.0 1.0 – – –
A3 10.0 10.0 – – 49.0 – 30.0 1.0 – – –
A4 10.0 10.0 – – – 49.0 30.0 1.0 – – –
B1 10.0 – 5.0 – 54.0 – 30.0 1.0 – – –
B2 10.0 – 5.0 – – 54.0 30.0 1.0 – – –
B3 10.0 – 10.0 – 49.0 – 30.0 1.0 – – –
B4 10.0 – 10.0 – – 49.0 30.0 1.0 – – –
C1 10.0 – – 4.0 55.0 – 30.0 1.0 – – –
C2 10.0 – – 4.0 – 55.0 30.0 1.0 – – –
C3 10.0 – – 8.0 51.0 – 30.0 1.0 – – –
C4 10.0 – – 8.0 51.0 30.0 1.0 – – –
D1 10.0 – – – 10.0 – – 1.0 79.0 – –
D2 10.0 – – – – – – 1.0 – 89.0 –
D3 10.0 – – – – – – 1.0 – – 89.0
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disintegration times at low compression forces. The disintegration times
were significantly longer at 70 N hardness, especially for ODTs pre-
pared with trehalose. Primojel-containing tablets (series C) exhibited
shorter disintegration times than the Kollidon-containing samples at
30 N and similar disintegration times as the Kollidon-containing sam-
ples at 50 N hardness, with the exception of C4, which was much longer
than A4. A jelling effect was observed for the Primojel-containing
samples when placed in the disintegrating medium; which resulted in
significantly longer disintegration times at higher hardness than other
compositions. This effect was especially strong for trehalose-containing
samples where the higher density and slower dissolution of the filler
provided enough time for gel formation. This gel slowed down the
disintegration process. Primojel-containing ODTs also exhibited the
highest sensitivity to both hardness and filler type from the aspect of
Fig. 1. Scanning Electron Micrographs of lysozyme (a), Pearlitol SD200 (b), Prosolv SMCC 90 (c), trehalose (d), Kollidon CL-SF (e), Polyplasdone XL-10 (f), Primojel
(g) and Pruv (h) in 100x magnification.
Table 2
Average angle of repose of the mixtures (n= 3, results are displayed as mean ± SD).
Series A1 A2 A3 A4 B1 B2 B3 B4
Average (°)± SD 17.3 ± 1.9 13.7 ± 0.7 15.0 ± 1.4 17.2 ± 1.4 17.6 ± 1.1 19.3 ± 2.0 19.8 ± 2.2 22.4 ± 6.1
Series C1 C2 C3 C4 D1 D2 D3
Average (°)± SD 21.7 ± 1.7 22.0 ± 2.0 21.7 ± 3.0 19.0 ± 0.6 24.2 ± 3.1 19.1 ± 2.5 23.8 ± 2.8
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disintegration. It is notable that increasing the disintegrant content had
a negative effect on the disintegration time in all cases, which could be
explained by the elastic nature of the polymers. An increased amount of
the disintegrant decreased the compressibility of the powder mixtures.
The lower tablet density decreased the swelling efficacy, since the
disintegrant swelled into the primary and secondary pores and less
energy remained for the rupture of the tablet texture.
The difference seen in the performance of series A and B may be
explained with their different textures (Fig. 4). The loosely agglomer-
ated particles of Kollidon CL-SF (Fig. 1e) underwent a strong frag-
mentation and only the primary particles of the disintegrant may be
identified (see white arrows on Fig. 4a, c, and e), which decreased their
swelling efficacy. This was especially true for tablets with trehalose
(Fig. 4e and f), which contained numerous secondary pores. By con-
trast, the agglomerates of Polyplasdone XL-10 (Fig. 1f) remained intact
during compression; therefore, the presence of smaller pores did not
affect their ability to disintegrate. The lubricant-covered spherical
Polyplasone XL-10 agglomerates can be clearly identified on the scan-
ning electron micrographs (see white arrows on Fig. 4b, d, and f).
As discussed above, the 30 N ODTs showed signs of minor edge
attrition in friability tests. There was no considerable difference in the
disintegration times of the 30 N and 50 N tablets, while 70 N resulted in
significantly longer disintegration times. Therefore, the 50 N ODTs
were selected to be tested for dissolution.
Based on the dissolution results (Fig. 5), it can be concluded that the
dissolution rates exhibited an exponential decay with an increase in
disintegration time. Series B ODTs exhibited the fastest dissolution,
followed by series A and then series C. Certain irregularities were noted
as well, which can be related to the composition of the tablets. The
dissolution rates of ODTs with trehalose were lower, as expected, based
on the exponential model. This may be explained by the fast dissolution
and uneven distribution of trehalose crystals (Fig. 4e, and f). Dissolu-
tion of the excipient may help the disintegration of the whole tablet;
however, the active ingredient could also remain entrapped in the
smaller fragments, resulting in a lower dissolution rate.
Beside the fast disintegration and drug liberation, the appropriate
enzymatic activity is still a key question of tablet performance. The
results revealed no significant difference in enzyme activity between
the two types of crospovidone used in this study, but ODTs with sodium
starch glycolate exhibited significantly better results (Fig. 6). It is no-
table that from the aspect of enzyme activity crospovidone-containing
samples exhibited considerable high sensitivity to the filler type, which
was not observed for the sodium starch glycolate-containing samples.
Additionally, the crospovidone-containing samples also exhibited sig-
nificantly lower enzyme activity values when trehalose was used as
filler. It is an interesting phenomenon that ODTs formulated with
mannitol and a higher hardness value had a higher enzyme activity,
despite the higher mechanical stress during tablet compression. A
possible explanation may be that the stronger contact between particles
of the active ingredient and mannitol provided better stabilization
against friction and thermal effects that can be experienced during
ejection and handling of the high-density tablets. ODTs with trehalose,
in which the scanning electron micrographs (Fig. 4e, and f) confirmed
the presence of secondary pores and uneven distribution of the
Fig. 2. The change of the tablet apparent density.
Table 3
Disintegration time of ODTs displayed in seconds as average (n= 6).
Hardness Series
A1 A2 A3 A4 B1 B2 B3 B4
30 N 31.7 25.5 39.3 67.3 9.3 6.3 10.0 8.3
50 N 36.9 28.6 41.4 86.5 13.4 21.9 14.0 18.9
70 N 29.1 166.4 104.9 107.1 21.4 18.6 13.8 49.0
Hardness Series
C1 C2 C3 C4 D1 D2 D3
30 N 20.5 14.0 12.9 16.1 9.6 25.5 29.7
50 N 38.6 26.6 27.0 357.6 12.4 78.0 47.7
70 N 70.4 409.4 206.1 783.8 59.1 234.5 161.0
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stabilizing agent, did not show the same phenomenon due to a lack of
strong contact between the particles. This effect may also be responsible
for the slight decrease in enzyme activity at high disintegrant contents,
meanwhile, the higher density values and stronger contact may explain
the extraordinary activity results of the sodium starch glycolate ODTs.
If all critical quality attributes, including disintegration time, dis-
solution speed and enzyme activity, are considered, the best perfor-
mance was provided by the B1. The B series with Polyplasdone XL-10
provided the shortest disintegration times and fastest dissolution speed,
regardless of filler type and tablet hardness. Furthermore, the enzyme
Fig. 3. The change of disintegration times.
Fig. 4. Scanning electron micrographs of the breaking surfaces of A3 30N (a), B3 30N (b), A3 70N. (c), B3 70N (d), A4 70N (e), B4 70N (f) tablets (white arrows are
indicating disintegrant particles).
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activity may be maintained above 90% when using low amount of
disintegrant and mannitol as a filler and using 70 N for hardness.
Therefore, in the second part of this study, the performance of this
composition was compared to various ready-to-use excipients.
When comparing the disintegration times, it was found that B1
exhibited superior disintegration properties over the different ready-to-
use excipients (Fig. 7a). Only D1, containing a mixture of the directly
compressible Prosolv Easytab and the filler/stabilizer mannitol showed
a similar performance at 30 N and 50 N hardness values. However,
ODTs formulated at 70 N exhibited significantly longer disintegration
times than B1. Prosolv ODT G2 and Ludiflash, excipients recommended
for the formulation of ODTs, showed significantly worse results at each
of the three hardness values. It should be noted, however, that the
disintegration times provided by these formulations were still under
30 s at 30 N. A possible explanation for this phenomenon may be the
difference in apparent densities of the compositions (Fig. 7b). It is no-
table that D1 exhibits significantly lower densities than all other com-
positions. These low-density values may also explain the low enzymatic
Fig. 5. Drug dissolution from ODTs with a 50 N hardness value, (a) series A, Kollidon CL-SF tablets. (A1: 5% superdisintegrant + mannitol; A2: 5% super-
disintegrant + trehalose; A3: 10% superdisintegrant + mannitol; A4: 10% superdisintegrant + trehalose), (b) series B, Polyplasdone XL 10 tablets (B1: 5%
superdisintegrant + mannitol; B2: 5% superdisintegrant + trehalose; B3: 10% superdisintegrant + mannitol; B4: 10% superdisintegrant + trehalose), (c) series C,
Primojel tablets (C1: 4% superdisintegrant + mannitol; C2: 4% superdisintegrant + trehalose; C3: 8% superdisintegrant + mannitol; C4: 8% super-
disintegrant + trehalose) (d) series D, tablets made from ready-to-use excipient composites (D1: Prosolv EASYtab; D2: Prosolv ODT G2; D3: Ludiflash).
Fig. 6. Results of the statistical analysis on the enzymatic activity.
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activity measured in the case of this composition (Fig. 7c). The bond
between the particles of lysozyme and mannitol was not strong enough
for an appropriate stabilizing effect. In the case of D2 and D3, the en-
zyme activity was excellent, probably due to the high density and the
higher mannitol content of these excipients. Nevertheless, it is note-
worthy that D3 was the only composition in which greater hardness and
density resulted in a decreased enzymatic activity. A possible ex-
planation is that D3 did not contain microcrystalline cellulose and may
have been less capable of “absorbing” the mechanical energy, which in
turn affected the enzyme activity negatively.
When looking at the drug dissolution results (Fig. 5d), B1 and D2
exhibited a similar, superior performance. In the case of D1, the dis-
solution speed was fast as expected based on the disintegration time;
however, the amount of dissolved drug was lower. A possible ex-
planation for this decrease may be that the first quick phase of the
disintegration process was provided by the fast dissolution of mannitol.
However, the agglomerates of Prosolv Easytab disintegrated at a lower
speed. Since part of the active ingredient particles was stuck in these
agglomerates, they could not dissolve as quickly as mannitol. D3
exhibited a slower, but complete, drug dissolution. The lower rate of
dissolution can be related to the lower disintegration time.
4. Conclusion
The main goals of this study were to incorporate an enzyme into
ODTs formulated by direct compression and to study how excipient
selection and manufacturing technology affected the physical proper-
ties and performance of the tablets. Results revealed that despite the
higher mechanical load experienced during compression, ODTs with
higher hardness values provided better stability for the enzyme against
post-compressional stress. This may be related to the higher tablet
density and stronger contact between the enzyme and stabilizing
agents. Using a well deformable stabilizer with a smaller particle size is
essential to ensure appropriate distribution of the particles and appro-
priate contact among the particles, and to avoid the formation of sec-
ondary pores, which could have a negative effect on enzyme activity.
Series B tablets - containing Polyplasdone® XL-10 - had the shortest
disintegration times (11 of 12 samples under 30 s), and they exhibited
the least sensitivity to tablet hardness and the applied filler. Series A
tablets - containing Kollidon CL-SF - had longer disintegration times
than series B, but more than half of the disintegration times were still
under 60 s. Series C tablets - containing Primojel - exhibited shorter or
simialr disintegration times than series A at lower hardness. A jelling
effect was observed for series C samples when placed in the disin-
tegrating medium; which resulted in significantly longer disintegration
times at higher hardness than other compositions. This effect was
especially strong for trehalose-containing samples. The dissolution rates
exhibited an exponential decay with an increase in disintegration time.
Series B ODTs exhibited the fastest dissolution, followed by series A and
then series C. Formulation B1 provided the shortest disintegration time
and fastest dissolution speed, regardless of tablet hardness.
The application of co-processed, ready-to-use excipient composites
may provide an easy solution for formulating ODTs, but their compo-
sition and physical performance (including particle size, compressi-
bility, and disintegration mechanism) should be critically evaluated
before selection. In this study, B1 formulated with individual excipients
exhibited superior disintegration properties over the different ready-to-
use excipients. B1 and D2 exhibited a similar, superior performance in
the dissolution studies. However, the amount of dissolved drug was
lower in the case of the ready-to-use excipient. This study demonstrated
that in certain cases, developing an individually customized formula-
tion may be more beneficial, especially if requirements of multiple
critical quality attributes are to be met. Our results also showed that
instead of increasing the amount of the disintegrant, selecting a dif-
ferently structured type of even the chemically same disintegrant may
provide a better solution for issues experienced during disintegration.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jddst.2018.12.012.
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